share_log

B of A Securities Reinstates Underperform on Regeneron Pharmaceuticals, Announces $565 Price Target

Benzinga ·  Dec 10, 2024 20:32  · Ratings

B of A Securities analyst Tim Anderson reinstates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Underperform and announces $565 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment